Diamyd Medical: Recombinant vaccine from Protein Sciences receives FDA approval

  Diamyd Medical: Recombinant vaccine from Protein Sciences receives FDA

Business Wire

STOCKHOLM -- January 17, 2013

Regulatory News:

The US Food and Drug Administration has approved Protein Sciences
Corporation’s vaccine Flublok for the prevention of seasonal influenza in
adults 18 to 49 years of age. Diamyd Medical holds about 8 percent of the
shares in Protein Sciences Corporation.

Flublok is a recombinant protein-based seasonal influenza vaccine and the
first influenza vaccine manufactured using recombinant technology that has
received marketing approval by the FDA. Protein Sciences Corporation is
planning to have a limited launch of the product in February 2013 with the
full launch occurring in time for the 2013/14 influenza season. More
information can be found at www.proteinsciences.com or www.flublok.com.

About Protein Sciences Corporation

Protein Sciences Corporation, founded in 1983, is a privately held
biotechnology company located in Meriden, Connecticut, USA. The Company
focuses on the development and commercialization of recombinant vaccines and
biopharmaceuticals based on the Company’s patented manufacturing platform BEVS
(Baculovirus Expression Vector System). Protein Sciences’ lead product
candidates are Flublok against seasonal influenza, and Panblok against
pandemic influenza.

Protein Sciences is one of only a few companies in the world to develop
recombinant vaccines produced in non-mammalian cells using genetically
modified baculovirus. Some advantages compared to traditional vaccine
manufacturing are that it requires less lead time to manufacture, the products
are not produced in eggs and therefore do not contain egg derivatives, and the
manufacturing does not require the use of live influenza virus, thimerosal or

Protein Sciences also partners with select companies on product development
and manufacturing, and sells proteins for research purposes. The Company is
for example the contract manufacturer of the active ingredient GAD for Diamyd
Medical’s antigen-based diabetes therapy Diamyd®.

Diamyd Medical holds about 8 percent of the shares in Protein Sciences
Corporation. On August 31, 2012, the carrying amount of this holding was MSEK

About Diamyd Medical

Diamyd Medical (STO:DIAMB) was founded in 1996 and is active in the field of
pharmaceutical development. Diamyd Medical is headquartered in Stockholm,
Sweden. The Company’s development project consists of the protein GAD65 for
the treatment and prevention of autoimmune diabetes. A Swedish
researcher-initiated Phase II study is ongoing to evaluate whether GAD65 can
prevent type 1 diabetes in children who are at high risk of developing the

Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation (USA)
and the diagnostics company Mercodia AB (Sweden).

Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the
Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is
available on the Company’s website: www.diamyd.com.

This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.

Diamyd Medical AB (publ) Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone:
+46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: info@diamyd.com. Reg. no:

This information was brought to you by Cision http://www.cisionwire.com


Peter Zerhouni
President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26.
E-mail: press@diamyd.com
Press spacebar to pause and continue. Press esc to stop.